PRISM Emerging MedDiagnostics Index Top Mover: Qualigen Therapeutics
Qualigen Therapeutics (QLGN) leads the Prism Emerging MedDiagnostics Index with a 53% gain on the release of three posters at the American Association of Cancer Research regarding its lead therapeutic program, QN-302. Trading was paused and resumed several times due to volatility.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.
